Century Therapeutics Revenue and Competitors

Location

$560M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Century Therapeutics's estimated annual revenue is currently $35.2M per year.(i)
  • Century Therapeutics's estimated revenue per employee is $125,214
  • Century Therapeutics's total funding is $560M.
  • Century Therapeutics's current valuation is $791.8M. (January 2022)

Employee Data

  • Century Therapeutics has 281 Employees.(i)
  • Century Therapeutics grew their employee count by 22% last year.

Century Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEO (ad interim)Reveal Email/Phone
3
VPReveal Email/Phone
4
VP, Analytical Development and Quality ControlReveal Email/Phone
5
Head CMC Regulatory AffairsReveal Email/Phone
6
SVP, General CounselReveal Email/Phone
7
SVP, Cell EngineeringReveal Email/Phone
8
VP / Immuno-OncologyReveal Email/Phone
9
VP Early DevelopmentReveal Email/Phone
10
VP Finance And OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Century Therapeutics?

Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.

keywords:N/A

$560M

Total Funding

281

Number of Employees

$35.2M

Revenue (est)

22%

Employee Growth %

$791.8M

Valuation

N/A

Accelerator

Century Therapeutics News

2022-04-17 - Century Therapeutics (NASDAQ:IPSC) Downgraded by Zacks ...

According to Zacks, “Century Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell...

2022-04-13 - Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we...

2022-03-30 - Century Therapeutics to Present at the 21st Annual Needham ...

Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we...

2021-08-12 - Century Therapeutics : Reports Second Quarter 2021 Financial Results and Business Updates (Form 8-K)

Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates Continued Company investment across our iPSC platforms, programs and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 Recent IPO with net proceeds of approximately $221M J ...

2021-05-05 - Century Therapeutics Expands Board of Directors with Key Appointments

PHILADELPHIA, May 5, 2021 /PRNewswire/ -- Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Joe Jimenez as Board Chair and Cynthia Butitta as a new Independent Direc ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$83.8M2827%N/A
#2
$83.8M2825%N/A
#3
$63.8M2831%N/A
#4
$56.2M2847%N/A
#5
$84.6M28513%N/A